IJSER Home >> Journal >> IJSER
International Journal of Scientific and Engineering Research
ISSN Online 2229-5518
ISSN Print: 2229-5518 6    
Website: http://www.ijser.org
scirp IJSER >> Volume 3,Issue 6,June 2012
Development and Validation of UV- Spectrophotometric Method for the determination of Doxazosin Mesylate in pharmaceutical Formulations
Full Text(PDF, )  PP.335-348  
Author(s)
N.V.S. NAIDU,T.NIRANJAN, K. BABUNAIDU P. SUGUNA
KEYWORDS
: Spectrophotometry: Doxazosin mesylate: FeCl3: 2, 2-Bipyridine: Oxidation Followed by complex formation.
ABSTRACT
A simple, sensitive, selective rapid economical spectrophotometric method was developed for the determination of post synaptic a-1 Adrino receptor antagonist Doxazosin mesylate in pure form and pharmaceutical formulations based on the oxidation of Fe3+ion in presence of drug and followed by orange red colored complex formation with 2.2- Bipyridine reagent at Ph 4 which are extractable at 520nm. Beer's law is obeyed in the concentration range 5-30 µg /ml. The developed method was applied directly and easily for the analysis of the Pharmaceutical formulations. R.S.D was found to be 0.4254 and Recovery 99.77% respectively. The method was completely validated and proven to be rugged. The interferences of the other ingredients and excipients were not observed. The repeatability and the performance of the proved method were established by point and internal hypothesis and through recovery studies.
References
1. K.S. Babamoto and W.T. Hirokawa. Drug Review: Doxazosin: A new a1–adrenergic antagonist. Clin Pharm. 11: 415–425 (1992).

2. H.L. Elliot, P.A. Meredith, and J.L. Reid. Pharmacokinetic overview of Doxazosin. Am. J. Cardiol. 59: 78G–81G (1987).

3. R.V. Carlson, R.R. Bailey, E.J. Begg, M.G. Cowlishaw, and J.R. Sharman. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin. Pharmacol. Ther. 40(5): 561–566 (1986).

4. M.G. Cowlishaw and J.R. Sharman. Doxazosin determination by high-performance liquid chromatography using fluorescence detection. J. Chromatogr. 344: 403–407 (1985). Figure 3. Doxazosin plasma profiles after single administrations of one doxazosin base tablet () and one doxazosin mesylate tablet (_) to four dogs in the fed state. Tablets contained 2 mg doxazosin.

5. H.G. Fouda, T.M. Twomey, and R.P. Schneider. Liquid chromatography analysis of doxazosin in human serum with manual and robotic sample preparation. J. Chromatogr. Sci. 26: 570–573 (1988)

6. G.P. Jackman, F. Colagrande, and W.J. Louis. Validation of a solidphase extraction high-performance liquid chromatographic assay for doxazosin. J. Chromatogr. 566: 234–238 (1991).

7. P. Sripalakit, P. Nermhom, and A. Saraphanchotiwitthaya. Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Sci. 43: 63–66 (2005).

8. P. Sripalakit, P. Nermhom, and A. Saraphanchotiwitthaya Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 20: 729–735 (2006).

9. Y.J. Kim, Y. Lee,M.J. Kang, J.S. Huh,M. Yoon, J. Lee, and Y.W. Choi. High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. Biomed. Chromatogr. 20: 1172–1177 (2006).

10. Y.H. Kwon, H.S. Gwak, S.J. Yoon, and I.K. Chun. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug.Dev. Ind. Pharm. 33: 824–829 (2007).

11. X. Wei, J. Yin, G. Yang, C. He, and Y Chen. On-line solid-phase extraction with a monolithic weak cation-exchange column and simultaneous screening of alpha1-adrenergic receptor antagonists in human plasma. J. Sep. Sci. 30: 2851–2857 (2007).

12. N.Ma,W. Liu, H. Li, B. Chen, Y. Zhu, X. Liu, F.Wang, D. Xiang, and B. Zhang. LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. J. Pharm. Biomed. Anal. 43: 1049–1056 (2007).

13. O.Y. Al-Dirbashi, H.Y. Aboul-Enein, M. Jacob, and K.M.S. Al-Qahtani. UPLC-MS/MS determination of doxazosine in human plasma. Anal. Bioanal. Chem. 385: 1439–1443 (2006).

14. H.Y. Ji, E.J. Park, K.C. Lee, andH.S. Lee.Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. J Sep Sci. 31(9): 1628– 1633(2008).

15. L. Conway, J.J. McNeil, J. Hurley, G.P. Jackman, H. Krum, L.G. Howes, andW.J. Louis. The effects of food on the oral bioavailability of doxazosin in hypertensive subjects. Drug. Invest. 6: 90–95 (1993).

16. P. Macheras, C. Reppas, and J.B. Dressman. Biopharmaceutics of orally administered drugs. EllisHorwood Limited, 1995, ISBN0-13- 108093-8, pp 89-123 (Chapter 5).

17. J.M. Green. A Practical Guide to Analytical Method Validation. Anal. Chem. 68: 305A–309A (1996).

18. V.P. Shah, K.K. Midha, J.W.A. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilveray, G. McKay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli, C.T. Viswanathan, and A. Yacobi.Workshop/conference report— bioanalyticalmethod validation—a revisit with a decade of progress. Pharm. Res. 17: 1551 (2000).

19. J.C. Miller and J.N. Miller. Statistics for Analytical Chemistry,Wiley, NY, 1984, pp. 90–98 (Chapter 4).

20. M.L. Chen, L. Lesko, and R.L. Williams. Measures of exposure versus measures of rate and extent of absorption. Clin. Pharmacokinet. 40(8): 565–572 (2001).

21. J.C. Erve, S.C. Vashishtha,W. DeMaio, and R.E. Talaat. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos. 35(6): 908–916 (2007).

22. L.L. De Zwart, C.J.M. Rompelberg, A.J.A.M. Sips, J. Welink, and J.G.M. Van Engelen. National Institute of Public Health and the Environment, RIVM Report 623860010, Bilthoven, Netherlands, 1999.

http://www.rivm.nl/bibliotheek/rapporten/623860010.html. Date accessed: 28 January, 2009. 23. E. Nelson, E.L. Knoechel,W.E. Hamlin, and J.G.Wagner. Influence of the absorption rate of tolbutamide on the rate of decline of blood sugar levels in normal humans. J. Pharm. Sci. 51: 509–514 (1962).

24. S. Furesz. Blood levels following oral administration of different preparations of novobiocin. Antibiotics and Chemotherapy 8: 446–449 (1958).

25. S.L. Lin, L. Lachman, C.J. Swartz, and C.F. Huebner. Preformulation investigation. I. Relation of salt forms and biological activity of an experimental antihypertensive. J. Pharm. Sci. 61(9): 1418–1422 (1972).

26. R.K. Verbeeck, I. Kanfer, and R.B.Walker. Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy. Eur. J. Pharm. Sci. 28(1-2): 1–6 (2006). Manuscript received February 24, 2009; revision received June 5, 2009.Dog #4 11.0 10.4

27. Uslu B. Voltametric Analysis of Alfuzosin HCL in Pharmaceuticals, Human Serum and simulated gastric juice. Electroanalysis (NY). 2002,1289-1294.

Untitled Page